Please assess the completion status of the following clinical trial:

Trial Title: Safety, Tolerability and Efficacy of Etelcalcetide in Hemodialysis Patients With Secondary Hyperparathyroidism

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subject provides written informed consent.~* Intact parathyroid hormone (PTH) at least 350 pg/mL.~* Corrected calcium at least 9.0 mg/dL.~* Hemoglobin at least 9.0 g/dL.~* Adequate hemodialysis three times per week.~* Excepting chronic renal failure, subject is judged to be in stable medical condition based on medical history, physical examination, and routine laboratory tests.~Exclusion Criteria:~* History or symptomatic ventricular dysrhythmias.~* History of angina pectoris or congestive heart failure~* History of myocardial infarction, coronary angioplasty, or coronary artery bypass grafting within the past 6 months.~* History of or treatment for seizure disorder.~* Recent (3 months) parathyroidectomy.~* Serum transaminases (alanine aminotransferase, aspartate aminotransferase) greater than two times the upper limit of normal at screening.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Etelcalcetide (Type: EXPERIMENTAL): Participants received etelcalcetide administered by intravenous injection at the end of each hemodialysis session three times a week (TIW). The starting dose level was 5 mg; dose escalation was to proceed to 10 and 20 mg pending safety review of the prior cohort.
- Placebo (Type: PLACEBO_COMPARATOR): Participants received placebo administered by intravenous injection at the end of each hemodialysis session three times a week (TIW).

Based on this trial design, predict the completion outcome and termination type (if applicable).